DDInter221 DDInter734
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora. The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.
Boceprevir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Boceprevir {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Fidaxomicin
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Boceprevir {u} (Compound) resembles {v} (Compound) Telaprevir
Telaprevir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Boceprevir {u} (Compound) resembles {v} (Compound) Telaprevir
Telaprevir {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Boceprevir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Boceprevir (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Boceprevir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Fidaxomicin (Compound)
Boceprevir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Boceprevir (Compound) resembles Telaprevir (Compound) and Telaprevir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Boceprevir (Compound) resembles Telaprevir (Compound) and Telaprevir (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Fidaxomicin (Compound)
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)